Silibinin attenuates cognitive deficits and decreases of dopamine and serotonin induced by repeated methamphetamine treatment

Ping Lu, Takayoshi Mamiya, Lingling Lu, Akihiro Mouri, Minae Niwa, Hyoung Chun Kim, Li Bo Zou, Taku Nagai, Kiyofumi Yamada, Takashi Ikejima, Toshitaka Nabeshima

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

Cognitive deficits are a core feature of patients with methamphetamine (METH) abuse. It has been reported that repeated METH treatment impairs long-term recognition memory in the novel object recognition test (NORT) in mice. Recent studies indicate that silibinin, a flavonoid derived from the herb milk thistle, has potent neuroprotective effects in cell cultures and several animal models of neurological diseases. However, its effect on the cognitive deficit induced by METH remains unclear. In the present study, we attempt to clarify the effect of silibinin on impairments of recognition memory caused by METH in mice. Mice were co-administered silibinin with METH for 7 days and then cognitive function was assessed by NORT after 7-day withdrawal. Tissue levels of dopamine and serotonin as well as their metabolites in the prefrontal cortex and hippocampus were measured 1 day after NORT. Silibinin dose-dependently ameliorated the impairment of recognition memory caused by METH treatment in mice. Silibinin significantly attenuated the decreases in the dopamine content of the prefrontal cortex and serotonin content of the hippocampus caused by METH treatment. We also found a correlation between the recognition values and dopamine and serotonin contents of the prefrontal cortex and hippocampus. The effect of silibinin on cognitive impairment may be associated with an amelioration of decreases in dopamine and serotonin levels in the prefrontal cortex and hippocampus, respectively. These results suggest that silibinin may be useful as a pharmacological tool to investigate the mechanisms of METH-induced cognitive impairments.

Original languageEnglish
Pages (from-to)387-393
Number of pages7
JournalBehavioural Brain Research
Volume207
Issue number2
DOIs
Publication statusPublished - 05-03-2010
Externally publishedYes

Fingerprint

Methamphetamine
Dopamine
Serotonin
Prefrontal Cortex
Hippocampus
Therapeutics
Milk Thistle
Animal Disease Models
Long-Term Memory
silybin
Neuroprotective Agents
Recognition (Psychology)
Flavonoids
Cognition
Cell Culture Techniques
Pharmacology

All Science Journal Classification (ASJC) codes

  • Behavioral Neuroscience

Cite this

Lu, Ping ; Mamiya, Takayoshi ; Lu, Lingling ; Mouri, Akihiro ; Niwa, Minae ; Kim, Hyoung Chun ; Zou, Li Bo ; Nagai, Taku ; Yamada, Kiyofumi ; Ikejima, Takashi ; Nabeshima, Toshitaka. / Silibinin attenuates cognitive deficits and decreases of dopamine and serotonin induced by repeated methamphetamine treatment. In: Behavioural Brain Research. 2010 ; Vol. 207, No. 2. pp. 387-393.
@article{ae455a9c0aaa46d18ee4aa0c822db767,
title = "Silibinin attenuates cognitive deficits and decreases of dopamine and serotonin induced by repeated methamphetamine treatment",
abstract = "Cognitive deficits are a core feature of patients with methamphetamine (METH) abuse. It has been reported that repeated METH treatment impairs long-term recognition memory in the novel object recognition test (NORT) in mice. Recent studies indicate that silibinin, a flavonoid derived from the herb milk thistle, has potent neuroprotective effects in cell cultures and several animal models of neurological diseases. However, its effect on the cognitive deficit induced by METH remains unclear. In the present study, we attempt to clarify the effect of silibinin on impairments of recognition memory caused by METH in mice. Mice were co-administered silibinin with METH for 7 days and then cognitive function was assessed by NORT after 7-day withdrawal. Tissue levels of dopamine and serotonin as well as their metabolites in the prefrontal cortex and hippocampus were measured 1 day after NORT. Silibinin dose-dependently ameliorated the impairment of recognition memory caused by METH treatment in mice. Silibinin significantly attenuated the decreases in the dopamine content of the prefrontal cortex and serotonin content of the hippocampus caused by METH treatment. We also found a correlation between the recognition values and dopamine and serotonin contents of the prefrontal cortex and hippocampus. The effect of silibinin on cognitive impairment may be associated with an amelioration of decreases in dopamine and serotonin levels in the prefrontal cortex and hippocampus, respectively. These results suggest that silibinin may be useful as a pharmacological tool to investigate the mechanisms of METH-induced cognitive impairments.",
author = "Ping Lu and Takayoshi Mamiya and Lingling Lu and Akihiro Mouri and Minae Niwa and Kim, {Hyoung Chun} and Zou, {Li Bo} and Taku Nagai and Kiyofumi Yamada and Takashi Ikejima and Toshitaka Nabeshima",
year = "2010",
month = "3",
day = "5",
doi = "10.1016/j.bbr.2009.10.024",
language = "English",
volume = "207",
pages = "387--393",
journal = "Behavioural Brain Research",
issn = "0166-4328",
publisher = "Elsevier",
number = "2",

}

Silibinin attenuates cognitive deficits and decreases of dopamine and serotonin induced by repeated methamphetamine treatment. / Lu, Ping; Mamiya, Takayoshi; Lu, Lingling; Mouri, Akihiro; Niwa, Minae; Kim, Hyoung Chun; Zou, Li Bo; Nagai, Taku; Yamada, Kiyofumi; Ikejima, Takashi; Nabeshima, Toshitaka.

In: Behavioural Brain Research, Vol. 207, No. 2, 05.03.2010, p. 387-393.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Silibinin attenuates cognitive deficits and decreases of dopamine and serotonin induced by repeated methamphetamine treatment

AU - Lu, Ping

AU - Mamiya, Takayoshi

AU - Lu, Lingling

AU - Mouri, Akihiro

AU - Niwa, Minae

AU - Kim, Hyoung Chun

AU - Zou, Li Bo

AU - Nagai, Taku

AU - Yamada, Kiyofumi

AU - Ikejima, Takashi

AU - Nabeshima, Toshitaka

PY - 2010/3/5

Y1 - 2010/3/5

N2 - Cognitive deficits are a core feature of patients with methamphetamine (METH) abuse. It has been reported that repeated METH treatment impairs long-term recognition memory in the novel object recognition test (NORT) in mice. Recent studies indicate that silibinin, a flavonoid derived from the herb milk thistle, has potent neuroprotective effects in cell cultures and several animal models of neurological diseases. However, its effect on the cognitive deficit induced by METH remains unclear. In the present study, we attempt to clarify the effect of silibinin on impairments of recognition memory caused by METH in mice. Mice were co-administered silibinin with METH for 7 days and then cognitive function was assessed by NORT after 7-day withdrawal. Tissue levels of dopamine and serotonin as well as their metabolites in the prefrontal cortex and hippocampus were measured 1 day after NORT. Silibinin dose-dependently ameliorated the impairment of recognition memory caused by METH treatment in mice. Silibinin significantly attenuated the decreases in the dopamine content of the prefrontal cortex and serotonin content of the hippocampus caused by METH treatment. We also found a correlation between the recognition values and dopamine and serotonin contents of the prefrontal cortex and hippocampus. The effect of silibinin on cognitive impairment may be associated with an amelioration of decreases in dopamine and serotonin levels in the prefrontal cortex and hippocampus, respectively. These results suggest that silibinin may be useful as a pharmacological tool to investigate the mechanisms of METH-induced cognitive impairments.

AB - Cognitive deficits are a core feature of patients with methamphetamine (METH) abuse. It has been reported that repeated METH treatment impairs long-term recognition memory in the novel object recognition test (NORT) in mice. Recent studies indicate that silibinin, a flavonoid derived from the herb milk thistle, has potent neuroprotective effects in cell cultures and several animal models of neurological diseases. However, its effect on the cognitive deficit induced by METH remains unclear. In the present study, we attempt to clarify the effect of silibinin on impairments of recognition memory caused by METH in mice. Mice were co-administered silibinin with METH for 7 days and then cognitive function was assessed by NORT after 7-day withdrawal. Tissue levels of dopamine and serotonin as well as their metabolites in the prefrontal cortex and hippocampus were measured 1 day after NORT. Silibinin dose-dependently ameliorated the impairment of recognition memory caused by METH treatment in mice. Silibinin significantly attenuated the decreases in the dopamine content of the prefrontal cortex and serotonin content of the hippocampus caused by METH treatment. We also found a correlation between the recognition values and dopamine and serotonin contents of the prefrontal cortex and hippocampus. The effect of silibinin on cognitive impairment may be associated with an amelioration of decreases in dopamine and serotonin levels in the prefrontal cortex and hippocampus, respectively. These results suggest that silibinin may be useful as a pharmacological tool to investigate the mechanisms of METH-induced cognitive impairments.

UR - http://www.scopus.com/inward/record.url?scp=74449084200&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=74449084200&partnerID=8YFLogxK

U2 - 10.1016/j.bbr.2009.10.024

DO - 10.1016/j.bbr.2009.10.024

M3 - Article

VL - 207

SP - 387

EP - 393

JO - Behavioural Brain Research

JF - Behavioural Brain Research

SN - 0166-4328

IS - 2

ER -